Zantac -- also known as ranitidine -- was a popular heartburn drug until 2020, when the Food and Drug Administration ordered it removed from pharmacy shelves because of a potential cancer risk. While ...
The carcinogen, known as NDMA, is not harmful in very small amounts. However, tests showed that there were excessive quantities of NDMA in Zantac, otherwise known as ranitidine. Multiple litigations ...
The overriding reason – and main ongoing risk — keeping the stock price down is litigation over GSK’s Zantac (generic Ranitidine) drug. A best-selling heartburn medication after its US approval in ...
The litigation began after the U.S. Food and Drug Administration in 2020 asked manufacturers to pull the drug off the market over concerns that ranitidine, the active ingredient in Zantac and ...